Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast

Journal of Molecular Biology

Volumn 425, Issue 2, 2013, Pages 444-456

  Mata Fink, Jordi ^a,b   Kriegsman, Barry ^a   Yu, Hui Xin ^a   Zhu, Hanna ^a   Hanson, Melissa C ^a   Irvine, Darrell J ^a,b,c   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

epitope mapping; gp120; HIV; libraries; yeast display

Indexed keywords

ANTIGEN; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENETICS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS; YEAST CELL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84872116415     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.11.010     Document Type: Article

References (79)

1. R. Pantophlet, and D.R. Burton GP120: target for neutralizing HIV-1 antibodies Annu. Rev. Immunol. 24 2006 739 769
2. J.R. Mascola, and D.C. Montefiori The role of antibodies in HIV vaccines Annu. Rev. Immunol. 28 2010 413 444
3. B. Korber, B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours Evolutionary and immunological implications of contemporary HIV-1 variation Br. Med. Bull. 58 2001 19 42
4. T. Zhou, L. Xu, B. Dey, A.J. Hessell, D. Van Ryk, and S.-H. Xiang Structural definition of a conserved neutralization epitope on HIV-1 gp120 Nature 445 2007 732 737
5. D.R. Burton, C.F. Barbas, M.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals Proc. Natl Acad. Sci. USA 88 1991 10134 10137
6. D.R. Burton, J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, and P.W. Parren Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 266 1994 1024 1027
7. A. Trkola, M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, and N. Sullivan Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J. Virol. 70 1996 1100 1108
8. M. Thali, J.P. Moore, C. Furman, M. Charles, D.D. Ho, J. Robinson, and J. Sodroski Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding J. Virol. 67 1993 3978 3988
9. M. Moulard, S.K. Phogat, Y. Shu, A.F. Labrijn, X. Xiao, and J.M. Binley Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes Proc. Natl Acad. Sci. USA 99 2002 6913 6918
10. A.F. Labrijn, P. Poignard, A. Raja, M.B. Zwick, K. Delgado, and M. Franti Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 J. Virol. 77 2003 10557 10565
11. L.M. Walker, M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, and J.-P. Julien Broad neutralization coverage of HIV by multiple highly potent antibodies Nature 477 2011 466 470
12. R. Pejchal, K.J. Doores, L.M. Walker, R. Khayat, P.-S. Huang, and S.-K. Wang A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield Science 334 2011 1097 1103
13. J.F. Scheid, H. Mouquet, N. Feldhahn, M.S. Seaman, K. Velinzon, and J. Pietzsch Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals Nature 458 2009 636 640
14. L.M. Walker, S.K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, and J.L. Goss Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 2009 285 289
15. L.M. Walker, M.D. Simek, F. Priddy, J.S. Gach, D. Wagner, and M.B. Zwick A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals PLoS Pathog. 2010 6
16. S.D.W. Frost, T. Wrin, D.M. Smith, S.L. Kosakovsky Pond, Y. Liu, and E. Paxinos Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection Proc. Natl Acad. Sci. USA 102 2005 18514 18519
17. A. Nandi, C. Lavine, P. Wang, I. Lipchina, P. Goepfert, and G. Shaw Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1 Virology 396 2010 339 348
18. D.N. Sather, and L. Stamatatos Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects Vaccine 28 2010 B8 B12
19. L. Chen, Y. Do Kwon, T. Zhou, X. Wu, S. O'Dell, and L. Cavacini Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120 Science 326 2009 1123 1127
20. T. Zhou, I. Georgiev, X. Wu, Z.-Y. Yang, K. Dai, and A. Finzi Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01 Science 329 2010 811 817
21. R. Pejchal, L.M. Walker, R.L. Stanfield, S.K. Phogat, W.C. Koff, and P. Poignard Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 Proc. Natl Acad. Sci. USA 107 2010 11483 11488
22. X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev, and C. Wang Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing Science 333 2011 1593 1602
23. J.F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, and T.Y.K. Oliveira Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding Science 333 2011 1633 1637
24. F. Klein, C. Gaebler, H. Mouquet, D.N. Sather, C. Lehmann, and J.F. Scheid Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein J. Exp. Med. 209 2012 1469 1479
25. H. Mouquet, M. Warncke, J.F. Scheid, M.S. Seaman, and M.C. Nussenzweig Enhanced HIV-1 neutralization by antibody heteroligation Proc. Natl Acad. Sci. USA 109 2012 875 880
26. X. Wu, Z.-Y. Yang, Y. Li, C.-M. Hogerkorp, W.R. Schief, and M.S. Seaman Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
27. G.D. Tomaras, J.M. Binley, E.S. Gray, E.T. Crooks, K. Osawa, and P.L. Moore Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals J. Virol. 85 2011 11502 11519
28. J.F. Scheid, H. Mouquet, N. Feldhahn, B.D. Walker, F. Pereyra, and E. Cutrell A method for identification of HIV gp140 binding memory B cells in human blood J. Immunol. Methods 343 2009 65 67
29. L.M. Walker, and D.R. Burton Rational antibody-based HIV-1 vaccine design: current approaches and future directions Curr. Opin. Immunol. 22 2010 358 366
30. D.R. Burton, R.C. Desrosiers, R.W. Doms, W.C. Koff, P.D. Kwong, and J.P. Moore HIV vaccine design and the neutralizing antibody problem Nat. Immunol. 5 2004 233 236
31. D.G. Myszka, R.W. Sweet, P. Hensley, M. Brigham-Burke, P.D. Kwong, and W.A. Hendrickson Energetics of the HIV gp120-CD4 binding reaction Proc. Natl Acad. Sci. USA 97 2000 9026 9031
32. P.D. Kwong, M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, and S. Majeed HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites Nature 420 2002 678 682
33. B. Dey, M. Pancera, K. Svehla, Y. Shu, S.-H. Xiang, and J. Vainshtein Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity J. Virol. 81 2007 5579 5593
34. R. Pantophlet, and D.R. Burton Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies Trends Mol. Med. 9 2003 468 473
35. R. Pantophlet, I.A. Wilson, and D.R. Burton Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design J. Virol. 77 2003 5889 5901
36. R. Pantophlet, I.A. Wilson, and D.R. Burton Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12 Protein Eng., Des. Sel. 17 2004 749 758
37. F.K. Ahmed, B.E. Clark, D.R. Burton, and R. Pantophlet An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site Vaccine 30 2012 922 930
38. S. Selvarajah, B. Puffer, R. Pantophlet, M. Law, R.W. Doms, and D.R. Burton Comparing antigenicity and immunogenicity of engineered gp120 J. Virol. 79 2005 12148 12163
39. J.M. Kovacs, J.P. Nkolola, H. Peng, A. Cheung, J. Perry, and C.A. Miller HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120 Proc. Natl Acad. Sci. USA 109 2012 12111 12116
40. J.P. Nkolola, H. Peng, E.C. Settembre, M. Freeman, L.E. Grandpre, and C. Devoy Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs J. Virol. 84 2010 3270 3279
41. W.R. Schief, Y.-E.A. Ban, and L. Stamatatos Challenges for structure-based HIV vaccine design Curr. Opin. HIV AIDS 4 2009 431 440
42. B.E. Correia, Y.-E.A. Ban, D.J. Friend, K. Ellingson, H. Xu, and E. Boni Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design J. Mol. Biol. 405 2011 284 297
43. E.T. Boder, and K.D. Wittrup Yeast surface display for screening combinatorial polypeptide libraries Nat. Biotechnol. 15 1997 553 557
44. E.T. Boder, K.S. Midelfort, and K.D. Wittrup Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity Proc. Natl Acad. Sci. USA 97 2000 10701 10705
45. Y.-S. Kim, R. Bhandari, J.R. Cochran, J. Kuriyan, and K.D. Wittrup Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast Proteins 62 2006 1026 1035
46. S.A. Gai, and K.D. Wittrup Yeast surface display for protein engineering and characterization Curr. Opin. Struct. Biol. 17 2007 467 473
47. G. Chao, J.R. Cochran, and K.D. Wittrup Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display J. Mol. Biol. 342 2004 539 550
48. Y. Li, H. Hui, C.J. Burgess, R.W. Price, P.M. Sharp, B.H. Hahn, and G.M. Shaw Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation J. Virol. 66 1992 6587 6600
49. P.D. Kwong, R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature 393 1998 648 659
50. M. Pancera, S. Majeed, Y.-E.A. Ban, L. Chen, C.-C. Huang, and L. Kong Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility Proc. Natl Acad. Sci. USA 107 2010 1166 1171
51. D.R. Burton, R.L. Stanfield, and I.A. Wilson Antibody vs HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102 2005 14943 14948
52. X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, and M.K. Gorny Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 J. Virol. 78 2004 12975 12986
53. L. Wu, T. Zhou, Z.-Y. Yang, K. Svehla, S. O'Dell, and M.K. Louder Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain J. Virol. 83 2009 5077 5086
54. P. Roben, J.P. Moore, M. Thali, J. Sodroski, C.F. Barbas, and D.R. Burton Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 J. Virol. 68 1994 4821 4828
55. M.R. Posner, T. Hideshima, T. Cannon, M. Mukherjee, K.H. Mayer, and R.A. Byrn An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection J. Immunol. 146 1991 4325 4332
56. C.N. Scanlan, R. Pantophlet, M.R. Wormald, E. Ollmann Saphire, R. Stanfield, and I.A. Wilson The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1 → 2 mannose residues on the outer face of gp120 J. Virol. 76 2002 7306 7321
57. R.W. Sanders, M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, and K.O. Lloyd The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120 J. Virol. 76 2002 7293 7305
58. K.J. Doores, C. Bonomelli, D.J. Harvey, S. Vasiljevic, R.A. Dwek, and D.R. Burton Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens Proc. Natl Acad. Sci. USA 107 2010 13800 13805
59. E. Celik, and P. CalIk Production of recombinant proteins by yeast cells Biotechnol. Adv. 30 2012 1108 1118
60. R.J. Luallen, J. Lin, H. Fu, K.K. Cai, C. Agrawal, and I. Mboudjeka An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies J. Virol. 82 2008 6447 6457
61. B. Korber, B.T. Foley, C. Kuiken, S.K. Pillai, and J.G. Sodroski Numbering positions in HIV relative to HXB2CG B. Korber, C.L. Kuiken, B. Foley, B. Hahn, F. McCutchan, J.W. Mellors, J. Sodroski, Human Retroviruses and AIDS 1998 1998 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory Los Alamos, NM III-102 111
62. A. Sali, and T.L. Blundell Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 234 1993 779 815
63. M. Thali, C. Furman, D.D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein J. Virol. 66 1992 5635 5641
64. Y. Li, S. O'Dell, L.M. Walker, X. Wu, J. Guenaga, and Y. Feng Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01 J. Virol. 85 2011 8954 8967
65. U. Olshevsky, E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sodroski Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding J. Virol. 64 1990 5701 5707
66. R. Pantophlet, E.O. Saphire, P. Poignard, P.W.H.I. Parren, I.A. Wilson, and D.R. Burton Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120 J. Virol. 77 2003 642 658
67. J. Pietzsch, J.F. Scheid, H. Mouquet, F. Klein, M.S. Seaman, and M. Jankovic Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness J. Exp. Med. 207 2010 1995 2002
68. S. Gnanakaran, M.G. Daniels, T. Bhattacharya, A.S. Lapedes, A. Sethi, and M. Li Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies PLoS Comput. Biol. 6 2010 e1000955
69. T. Oliphant, M. Engle, G.E. Nybakken, C. Doane, S. Johnson, and L. Huang Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus Nat. Med. 11 2005 522 530
70. T. Han, J. Sui, A.S. Bennett, R.C. Liddington, R.O. Donis, Q. Zhu, and W.A. Marasco Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display Biochem. Biophys. Res. Commun. 409 2011 253 259
71. J.B. Spangler, J.R. Neil, S. Abramovitch, Y. Yarden, F.M. White, D.A. Lauffenburger, and K.D. Wittrup Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling Proc. Natl Acad. Sci. USA 107 2010 13252 13257
72. R. Levy, C.M. Forsyth, S.L. LaPorte, I.N. Geren, L.A. Smith, and J.D. Marks Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display J. Mol. Biol. 365 2007 196 210
73. T. Oliphant, G.E. Nybakken, M. Engle, Q. Xu, C.A. Nelson, and S. Sukupolvi-Petty Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein J. Virol. 80 2006 12149 12159
74. G. Chao, W.L. Lau, B.J. Hackel, S.L. Sazinsky, S.M. Lippow, and K.D. Wittrup Isolating and engineering human antibodies using yeast surface display Nat. Protoc. 1 2006 755 768
75. R. Grantham Amino acid difference formula to help explain protein evolution Science 185 1974 862 864
76. D. Bordo, and P. Argos Suggestions for "safe" residue substitutions in site-directed mutagenesis J. Mol. Biol. 217 1991 721 729
77. C. Chothia, and J. Janin Principles of protein-protein recognition Nature 256 1975 705 708
78. F. Melo, R. Sánchez, and A. Sali Statistical potentials for fold assessment Protein Sci. 11 2002 430 448
79. B. John, and A. Sali Comparative protein structure modeling by iterative alignment, model building and model assessment Nucleic Acids Res. 31 2003 3982 3992